Trial Profile
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Sep 2023
Price :
$35
*
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Salbutamol; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 03 Dec 2021 Results assessing the cost-effectiveness of once-daily fluticasone furoate-umeclidinium-vilanterol 100-62.5-25 microgm compared with once-daily tiotropium 18 microgm in patients with symptomatic chronic obstructive pulmonary disease and a history of exacerbations from UK National Healthcare System perspective, presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 21 Oct 2020 Results of post-hoc analysis presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians.
- 20 May 2020 Primary endpoint, Change from Baseline in trough forced expiratory volume in 1 second (FEV1) at Day 85, has been met as per results presented at the 116th International Conference of the American Thoracic Society